Genenta Science (NASDAQ:GNTA) Stock Price Down 0.3% – Here’s Why

Posted by ABMN Staff on Apr 22nd, 2025

Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report) shares were down 0.3% during mid-day trading on Monday . The stock traded as low as $3.51 and last traded at $3.87. Approximately 14,252 shares were traded during trading, a decline of 5% from the average daily volume of 15,064 shares. The stock had previously closed at $3.88.

Genenta Science Trading Down 0.3 %

The business has a 50-day moving average price of $3.89 and a 200 day moving average price of $4.51.

Institutional Trading of Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. Allianz SE bought a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 103,250 shares of the company’s stock, valued at approximately $444,000. Allianz SE owned about 0.56% of Genenta Science as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

(Get Free Report)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.